BrainStorm Cell Therapeutics Inc.
Tel Aviv
372 articles with BrainStorm Cell Therapeutics Inc.
-
BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing
12/7/2021
BrainStorm Cell Therapeutics Inc. and Catalent today announced that the technology transfer for NurOwn® manufacturing at Catalent's facility has been finalized.
-
BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND
12/2/2021
BrainStorm Cell Therapeutics Inc. today announced that biomarker data on NurOwn® will be presented at the 32nd International Symposium on ALS/MND, to be held virtually 7-10 December 2021.
-
BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium
11/29/2021
BrainStorm Cell Therapeutics Inc. today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium.
-
BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
11/15/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the quarter ended September 30, 2021, and provided a corporate update.
-
BioSpace Movers & Shakers, Nov. 12
11/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
11/8/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments as the company prepares for future growth.
-
Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors
10/28/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced the appointment of Menghis Bairu, MD, to the company's Board of Directors.
-
BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update
10/25/2021
BrainStorm Cell Therapeutics Inc. announced today that the Company will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2021 , and provide a corporate update, at 8:00 a.m. Eastern Time
-
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting
10/18/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benefits of MSC-NTF (NurOwn®) Exosomes in Acute Lung Injury Models" at the NYSCF 2021 VIRTUAL Meeting, being held on October 19-20, 2021.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
10/14/2021
BrainStorm Cell Therapeutics Inc. will present findings from a multicenter, open label clinical trial of NurOwn® in progressive multiple sclerosis.
-
BrainStorm announced positive data from a Phase II safety and efficacy study of NurOwn in progressive MS on Thursday morning.
-
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021
10/6/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial" will be presented as a scientific poster at the fully digital 2021 Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS) conference.
-
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa
10/4/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference October 12-14, and October 19-20, 2021.
-
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
10/1/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that a scientific abstract titled "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis" will be presented in an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
-
Amylyx’s decision to submit the NDA, announced Wednesday morning, came on the heels of recent discussions with the FDA, including a pre-NDA meeting held on July 15.
-
BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
8/5/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the first quarter ended June 30, 2021 and provided a corporate update.
-
The panels discussed key issues such as expanded access programs (EAPs), clinical trial diversity, conditional approval pathways, and patient experience data.
-
BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel
7/27/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that is has received Good Manufacturing Practice approval from the Israel Ministry of Health for three state-of-the-art cleanrooms leased by the Company at the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.
-
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
7/26/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on August 05, 2021.